18β-Glycyrrhetinic Acid-Loaded ROS-Responsive Liposomes Enhance the Neuroprotective Efficacy against Cerebral Ischemic Stroke in Mice via a Microenvironment-Responsive Strategy
{"title":"18β-Glycyrrhetinic Acid-Loaded ROS-Responsive Liposomes Enhance the Neuroprotective Efficacy against Cerebral Ischemic Stroke in Mice via a Microenvironment-Responsive Strategy","authors":"Yu Wang, Guan Wang, Xuenan Zhou, Xiaodi Zhang, Fang Li, Kexin Meng, Peng Wang, Jia Liang","doi":"10.1021/acs.molpharmaceut.6c00493","DOIUrl":null,"url":null,"abstract":"<p>18β-Glycyrrhetinic acid (GA) exhibits excellent anti-inflammatory and antioxidant activities, and has attracted considerable attention in the field of cerebral ischemia−reperfusion (I/R) injury therapy. However, it is plagued by problems of low bioavailability and dose-dependent toxicity. As a drug delivery platform for the treatment of ischemic stroke, microenvironment-responsive liposomes can cross the impaired blood−brain barrier, efficiently deliver drugs to the lesion sites, and improve therapeutic efficacy. Herein, to address the challenges posed by the highly oxidative-stress microenvironment of I/R and the intrinsic physicochemical properties of GA, we encapsulated GA into liposomes and incorporated thioketal (TK) linkages into the phospholipid bilayer to fabricate GA@TK-Lip. GA@TK-Lip can effectively target damaged neurons, attenuate neuroinflammation, scavenge excessive ROS, ameliorate cellular oxidative stress via the Nrf2/HO-1 pathway, reduce neuronal apoptosis and cerebral infarct volume to 43.2% and 23.3% of that in the MCAO group, and restore neurological function. Collectively, this study provides novel insights into the development of promising therapeutic strategies for ischemic stroke.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4921–4934"},"PeriodicalIF":4.9000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.6c00493","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
18β-Glycyrrhetinic acid (GA) exhibits excellent anti-inflammatory and antioxidant activities, and has attracted considerable attention in the field of cerebral ischemia−reperfusion (I/R) injury therapy. However, it is plagued by problems of low bioavailability and dose-dependent toxicity. As a drug delivery platform for the treatment of ischemic stroke, microenvironment-responsive liposomes can cross the impaired blood−brain barrier, efficiently deliver drugs to the lesion sites, and improve therapeutic efficacy. Herein, to address the challenges posed by the highly oxidative-stress microenvironment of I/R and the intrinsic physicochemical properties of GA, we encapsulated GA into liposomes and incorporated thioketal (TK) linkages into the phospholipid bilayer to fabricate GA@TK-Lip. GA@TK-Lip can effectively target damaged neurons, attenuate neuroinflammation, scavenge excessive ROS, ameliorate cellular oxidative stress via the Nrf2/HO-1 pathway, reduce neuronal apoptosis and cerebral infarct volume to 43.2% and 23.3% of that in the MCAO group, and restore neurological function. Collectively, this study provides novel insights into the development of promising therapeutic strategies for ischemic stroke.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.